Piper Sandler Reiterates Neutral on Collegium Pharmaceutical, Lowers Price Target to $43

Benzinga Newsdesk www.benzinga.com Negative 87.5%

Neg 87.5% Neu 0% Pos 0%

Piper Sandler analyst David Amsellem reiterates Collegium Pharmaceutical (NASDAQ:COLL) with a Neutral and lowers the price target from $45 to $43.